Every year, the meeting of the American Society of Clinical Oncology, or ASCO, is one of the biggest events for the biotech industry, both in terms of catching up on the latest in cancer treatment, but also for Wall Street and its outlook on biotech stocks.
And this year’s meeting comes as biotech stocks have been in the doldrums, with one benchmark index down more than 40% in the last 12 months. So what does this weekend hold and what could it do for biotech’s terrible, horrible, no good, very bad year?
Create a display name to comment
This name will appear with your comment
